Mobia Medical began trading on Nasdaq after pricing its IPO at $15 per share, raising about $150 million. The company’s lead therapy, Vivistim Paired VNS, is a vagus-nerve stimulation approach designed to improve upper-limb function in chronic ischemic stroke survivors with moderate-to-severe impairments. The first-day trading move reflected investor recalibration immediately after listing, but the offering increases visibility and potential scale for a commercial-stage neuromodulation product aiming to address a persistent unmet need in stroke rehabilitation. With neuromodulation increasingly part of the broader neurotherapeutics landscape, Mobia’s listing also signals continued capital access for device-adjacent clinical programs tied to neurologic outcomes.